LSP Founded -
Overview
Portfolio analytics
Team
Investments
News & Media
Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 3
Average round size
info
The average size of a deal this fund participated in
$30M
Portfolio companies 3
Lead investments 2
Areas of investment
Biotechnology
Health Care
Industrial
Summary

Moreover, a startup needs to be at the age of 11-15 years to get the investment from the fund. Among the most successful fund investment fields, there are Medical Device, Therapeutics. Among the most popular portfolio startups of the fund, we may highlight iSTAR Medical, Xeltis. The fund has specific favorite in a number of founders of portfolio startups.

The standard case for the fund is to invest in rounds with 4 partakers. Despite the LSP, startups are often financed by VI Partners AG, Life Sciences Partners, Kurma Partners. The meaningful sponsors for the fund in investment in the same round are SFPI-FPIM, S.R.I.W., Gimv.

The top activity for fund was in 2019. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in 2-6 deals per year.

Read more
Notable deals
CompanyIndustryRoundRound SizeDateInvestorsLocation
eTheRNA immunotherapies
Biotechnology
Medical Device
Therapeutics
Early Stage Venture
40M16 Jun 2020 Belgium, " Belgium"}
Xeltis
Health Care
Medical Device
Therapeutics
Late Stage Venture
12M06 Sep 2019 Switzerland, Zurich
iSTAR Medical
Health Care
Manufacturing
Medical Device
Late Stage Venture
40M05 Sep 2019 Belgium, " Belgium"}
News
T-knife Therapeutics Closes $110M Series B Financing
– T-knife Therapeutics, Inc. from Berlin, Germany develops T-cell receptor (TCR) therapeutics for solid tumor patients. – Company completed a $110m Series B financing. – The round was led by Fidelity Management & Research Company, LLC., with participation from other new investors including LSP, Qatar Investment Authority (QIA), Casdin Capital, Sixty Degree Capital, and CaaS Capital, along with existing investors RA Capital Management, Versant Ventures and founding investor Andera Partners. – The new i... Read more
Review
  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent LSP?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: